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Pneumocystis carinii pneumonia (PCP) in
humans, caused by the opportunistic fungal
pathogen Pneumocystis carinii f. sp. hominis, is a
frequent cause of illness in persons with AIDS. In
recent years, the number of new cases of PCP has
greatly diminished (1), largely as a result of
highly active antiretroviral therapy and effective
anti-Pneumocystis chemoprophylaxis, primarily
with trimethoprim-sulfamethoxazole (TMP-SMZ).
However, PCP is still the most common life-
threatening AIDS indicator condition in the
United States in patients whose CD4+ cell count
has declined to < 200 cells/µL for the first time (2).
The number of persons at risk, as measured by
the number of HIV-infected patients with CD4+
cell counts < 200 cells/µL, was recently estimated
at around 182,000 (3).
Despite the frequency of PCP, tremendous
gaps exist in understanding the basic biology and
epidemiology of the causal agent. These gaps,
which have been reviewed extensively (4-9),
include lack of knowledge of population structure
of P. carinii strains circulating among patients or
in potential environmental reservoirs. The
implications are important for understanding
patterns of transmission and developing methods
of intervention.
In the last 5 years, a substantial number of
genes and gene fragments have been identified
for potential use in analysis and characterization
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To study transmission patterns of Pneumocystis carinii pneumonia (PCP) in
persons with AIDS, we evaluated P. carinii isolates from patients in five U.S. cities for
variation at two independent genetic loci, the mitochondrial large subunit rRNA and
dihydropteroate synthase. Fourteen unique multilocus genotypes were observed in 191
isolates that were examined at both loci. Mixed infections, accounting for 17.8% of
cases, were associated with primary PCP. Genotype frequency distribution patterns
varied by patients’ place of diagnosis but not by place of birth. Genetic variation at the
two loci suggests three probable characteristics of transmission: that most cases of PCP
do not result from infections acquired early in life, that infections are actively acquired
from a relatively common source (humans or the environment), and that humans, while
not necessarily involved in direct infection of other humans, are nevertheless important
in the transmission cycle of P. carinii f. sp. hominis.Resear Resear Resear Resear Research ch ch ch ch
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of  P. carinii strains. These loci include the
mitochondrial large subunit ribosomal RNA gene
(mtlsurRNA) (10-12) and the internal tran-
scribed spacers of the nuclear ribosomal RNA
array (12-14). The dihydropteroate synthase
(DHPS) gene locus, which encodes a target for the
anti-Pneumocystis drugs TMP-SMZ and dap-
sone, has also been cloned and sequenced (15).
Substantial variation at this locus (16,17)
suggests that the widespread use of antimicro-
bial chemoprophylaxis may be exerting selective
pressure on P. carinii strains circulating in
humans. Its polymorphism makes the locus not
only potentially useful as a marker for changes in
antimicrobial susceptibility levels, but also
valuable for strain characterization and typing.
We examined polymorphism at two genetic
loci of P. carinii isolates from persons with AIDS
diagnosed in five U.S. cities. One locus,
mtlsurRNA, is involved in basic metabolic
functions, and the other, DHPS, is the target of
sulfone and sulfonamide antimicrobial drugs. We
examined the population structure of P. carinii




Specimens used in the study were obtained
from March 1995 to June 1998 during routine
diagnostic procedures for HIV-infected patients
hospitalized with PCP in Atlanta, Cincinnati, Los
Angeles, San Francisco, and Seattle. A portion of
the diagnostic specimen, either induced sputum
or bronchoalveolar lavage, was preserved
directly with an equal volume of absolute ethanol
and stored at 4°C for DNA extraction.
DNA Purification
Specimens were divided into approximately
1-mL aliquots and centrifuged at 14,000 x g for 5
to 7 minutes. The resulting cell pellet was
resuspended in 1 mL of phosphate-buffered saline
(0.01M, pH 7.2) containing 1 mM EDTA (PBS-
EDTA), washed twice in PBS-EDTA, centrifuged,
and stored at -80°C for later DNA extraction.
DNA was prepared by a commercial purification
procedure (Wizard Genomic DNA Purification
Kit, Promega, Madison, WI) in accordance with
the product recommendations for DNA purifica-
tion from blood. Final pellets were resuspended
in 50 µL of TE (10 mM Tris, 1 mM EDTA, pH 7.2).
Polymerase Chain Reaction (PCR)
and DNA Sequencing
PCR amplification was performed at two
independent genetic loci. A 360-bp fragment was
amplified from the mtlsurRNA locus by using the
published primers PAZ102E (5' - GAT GGC TGT
TTC CAA GCC CA - 3') and PAZ102H (5' - GTG
TAC GTT GCA AAG TAC TC - 3') (10). PCR
conditions included a 94°C hot start for 5
minutes; followed by 35 cycles of a program
consisting of 92°C for 30 seconds, 55°C for 30
seconds, and 72°C for 60 seconds; followed by a
termination step at 72°C for 5 minutes. The
DHPS locus was amplified by a modification of a
nested PCR procedure (16,17). In the first round
of this PCR, the primers DHPS F1 (5' - CCT GGT
ATT AAA CCA GTT TTG CC - 3') (S.R. Meshnick,
pers. comm.) and DHPS B45 (5' - CAA TTT AAT
AAA TTT CTT TCC AAA TAG CAT C - 3') (16)
were used. In the second round, the primers
DHPS AHUM (5' - GCG CCT ACA CAT ATT ATG
GCC ATT TTA AAT C - 3') and DHPS BN (5' -
GGA ACT TTC AAC TTG GCA ACC AC - 3') (16)
were used. The conditions for the first round were
94°C for 5 minutes, followed by 35 cycles of 92°C
for 30 seconds, 52°C for 30 seconds, 72°C for 60
seconds, and a termination step at 72°C for 5
minutes. The conditions for the second round of
PCR were 94°C for 5 minutes, then 35 cycles of
92°C for 30 seconds, 55°C for 30 seconds, and
72°C for 60 seconds, followed by a termination
step at 72°C for 5 minutes.
For analysis of the PCR-generated frag-
ments, 10 µL of each 50-µL PCR amplification
product was examined by horizontal gel
electrophoresis on 1% agarose gels. The
remaining 40 µL of successfully amplified
reactions was purified by a commercial purifica-
tion procedure (Wizard PCR Purification Kit,
Promega, Madison, WI) and suspended in 50 µL
of TE for DNA sequencing; 5 µL to 10 µL of each
purified product was sequenced directly by using
dye terminator chemistry (ABI Prism BigDye
Terminator Cycle Sequencing Ready Reaction
Kit, PE Applied Biosystems, Foster City, CA)
according to the manufacturer’s protocol, with
the DNA oligonuceotide primers used for PCR
amplification. The PCR fragments were se-
quenced on an ABI 377 automated DNA
sequencer (PE Applied Biosystems, Foster City,
CA) according to manufacturer’s recommenda-
tions. The sequenced DNA fragments were
analyzed by using Sequence Navigator v.1.0.1Resear Resear Resear Resear Research ch ch ch ch
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Table 1. Genotype analysis of Pneumocystis carinii
isolates at the mtlsurRNA locus
    Nucleotide Frequency
Genotype position/identity n=324 (%)
1 85/C; 248/C 123 (38.0)
2 85/A; 248/C 119 (36.7)
3 85/T; 248/C   30 (9.3)
4 85/C; 248/T   19 (5.9)
mixed   33 (10.2)
Table 2. Genotype analysis of Pneumocystis carinii
isolates at the DHPS locus
Nucleotide (amino acid) Frequency
Genotype       position/identity n=220 (%)
1 165 (55)/A (Thr)   68 (30.9)
171 (57)/C (Pro)
2 165 (55)/G (Ala)   13 (5.9)
171 (57)/C (Pro)
3 165 (55)/A (Thr)     5 (2.3)
171 (57)/T (Ser)
4 165 (55)/G (Ala) 109 (49.5)
171 (57)/T (Ser)
mixed   25 (11.4)
(PE Applied Biosystems, Foster City, CA) and the
GCG Wisconsin Package Version 9.1. computer
program (18).
Statistical Analysis
Statistical analyses were performed with
SAS software version 6.12. Logistic regression
was used to examine the association between
place of diagnosis and place of birth and genotype
for mtlsurRNA and DHPS gene loci.
Results
 Amplification with Specific Primers
PCR amplification with the selected primer
sets gave consistent results in most P. carinii-
positive samples. The mtlsurRNA primers
amplified a 360-bp fragment in 223 samples from
Atlanta, Los Angeles, San Francisco, and Seattle.
The  DHPS primer sets amplified a 300-bp
fragment in 220 of these samples. Both genetic
loci were successfully amplified for 191 samples.
In the Cincinnati dataset, 101 samples were
amplified for the mtlsurRNA locus. The DHPS
site was not examined for this group of samples.
All the amplified fragments were sequenced,
aligned, and examined for genetic polymorphism.
General Observations on Genotype Frequency
Four unique genotypes were observed for
each of the two genetic loci examined. At the
mtlsurRNA locus, all the genotypes were
distinguished on the basis of polymorphism at
nucleotide positions 85 and 248. Genotypes 1
(85:C; 248:C) and 2 (85:A; 248:C) were the most
common (Table 1), occurring at similar frequen-
cies and together accounting for 74.7% of the 324
samples analyzed. Genotypes 3 (85:T; 248:C) and
4 (85:C; 248:T) accounted for 9.3% and 5.9%,
respectively. At the DHPS locus, genotypes 1 and
4 accounted for 80.4% of all samples (Table 2).
Genotypes 2 and 3 were both relatively
uncommon, seen in 5.9% and 2.3% of the samples
analyzed, respectively. All the mutations seen at
this locus were nonsynonymous changes result-
ing in amino acid substitutions; no other
polymorphism was observed. Genotype 1 was the
designation used to refer to the sequence defined
by a threonine at position 55 and a proline at
position 57. Genotype 2 referred to an alanine at
55 and a proline at 57, Genotype 3 to a threonine
at position 55 and a serine at 57, and genotype 4
to an alanine at position 55 and a serine at
position 57.
When the results at both genetic loci were
combined, 14 unique multilocus genotypes of 16
possible combinations were observed in 191
samples for which both genes could be amplified
and sequenced. The four most common multilocus
genotypes accounted for 61.7% of all genotypes.
The most common multilocus genotypes con-
sisted of combinations of the most common
genotypes at each individual locus. No genetic
linkage of specific genotypes from the two loci
was observed.
Coinfection with multiple P. carinii strains
could be detected in 33 (10.2%) of 324 samples
typed at the mtlsurRNA locus and 25 (11.4%) of
220 typed at the DHPS locus. When the
genotypes were considered together, 34 (17.8%)
of 191 samples represented coinfections with
multiple genotypes. When these samples were
analyzed according to patient history, 21 (17.6%)
of 119 samples from patients with no history of
previous PCP were coinfected with multiple
strains, by typing at the mtlsurRNA locus. In
contrast, none of the samples from 41 patients
with PCP history had multiple genotypes (p =
0.002, Fisher’s exact test). A similar trend was
observed at the DHPS locus but was not
statistically significant.Resear Resear Resear Resear Research ch ch ch ch
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Figure 1. Distribution of Pneumocystis carinii mtlsurRNA
genotypes, by city (chi-square test, p = .001)
Atlanta, n = 76; Cincinnati, n = 107; Los Angeles, n = 15; San
Francisco, n = 68; Seattle, n = 57.
Figure 2. Distribution of Pneumocystis carinii DHPS
genotypes by city (Fisher’s exact test, p=.049).
Atlanta, n=80; Los Angeles, n=20;  San Francisco, n=66;
Seattle, n=53.
Genotype Frequency Distribution
Patterns by Geographic Location
Genotype frequencies in PCP isolates
differed by city (Figures 1, 2). At the mtlsurRNA
locus (Figure 1), the genotype distribution was
significantly different (chi-square test; p = 0.001),
with the ratio of genotype 1 to genotype 2 ranging
from 0.7 in San Francisco to 1.8 in Cincinnati.
Analysis of the mtlsurRNA genotype frequencies
at each city showed that genotype distributions
also differed significantly or borderline signifi-
cantly, with p values from 0.001 to 0.08, with the
exception of Los Angeles. Comparisons involving
Los Angeles were nonsignificant, perhaps as a
result of small sample size (n = 15).
We used logistic regression to investigate
whether the geographic distribution was associ-
ated more with place of birth or with place of
diagnosis. We grouped places of birth and
diagnosis into either “east” or “west,” using the
Mississippi River as the dividing line. Data from
Cincinnati were not included, since place-of-birth
information was not available there. None of the
four  mtlsurRNA genotypes was significantly
associated with place of birth when the data were
adjusted for place of diagnosis. However, genotypes
2 and 4 were significantly associated with place of
diagnosis, when the data were adjusted for place
of birth (p = 0.002, p = 0.05, respectively); the
association of genotype 1 with place of diagnosis
was borderline significant (p = 0.08).
The overall genotype distribution at the
DHPS gene locus (Figure 2) also differed
significantly (Fisher’s exact test; p = 0.045) for
the various cities. The ratios of genotype 4 to
genotype 1 ranged from 0.97:1 in Atlanta to 3.13:1
in San Francisco. No isolates from Cincinnati
were analyzed at the DHPS locus.
Logistic regression analysis of the DHPS
genotypes by place of diagnosis and place of birth
showed results similar to those for the
mtlsurRNA genotypes. Genotypes 1 and 4 were
associated with place of diagnosis (p = 0.001, p =
0.002, respectively) when data were adjusted for
place of birth. In contrast, place of birth was not
associated with any DHPS genotype when data
were adjusted for place of diagnosis.
Discussion
P. carinii, once thought to be a protozoon but
now regarded an ascomycetelike fungus (4,19,20),
has been associated with human disease since
the 1940s. Despite intense efforts to understand
this important disease agent, lack of a suitable
means of propagation has complicated study of
basic biology and epidemiology. Similarly,
latency and reactivation (versus recent acquisi-
tion) have not been resolved. PCR and other
molecular methods have improved understand-
ing of genetic variability and host specificity
(11,12,14,20,21), as well as the cause of recurrent
infections in persons with AIDS (8,22-24).
Both an indirect (environmental) source and
a direct (person-to-person) source have been
proposed as modes of transmission of P. carinii in
humans. Three primary observations reported in
this study address infection sources and
transmission patterns: geographic variation inResear Resear Resear Resear Research ch ch ch ch
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genotype frequency distribution, which was
correlated with the place of diagnosis rather than
the place of birth; rate of coinfection with
multiple P. carinii genotypes, which was greater
in patients with primary rather than secondary
PCP; and abundance of the DHPS double mutant,
which accounted for 49.5% of all DHPS
genotypes, strongly suggesting genetic selection.
Allelic frequency distribution patterns of P.
carinii isolates were associated with place of
diagnosis rather than place of birth. Place of
diagnosis was determined more reliable than
place of residence as the best indicator of the most
likely place of exposure to P. carinii because place
of residence was frequently recorded as
permanent or legal residence rather than as
place of residence during the 3- to 6-month period
before admission. These results suggest that
infection in adults is acquired later than the first
few months or years of life and that any latency
has natural limits. Two independent lines of
study offer a context for these observations and
suggest that PCP is an actively acquired
infection. The first line of study comprises
molecular genetic analyses of P. carinii strains
from adult AIDS patients with recurrent PCP.
These analyses have shown that different
P. carinii genotypes are detected on subsequent
PCP episodes in a substantial proportion of
patients (22,23), which suggests that infections
in adults are actively acquired and that
subsequent infections do not necessarily repre-
sent relapses. The second line of study comprises
observations of primary PCP in infants with
perinatally acquired HIV infection (25) who had
PCP episodes at 3 to 6 months of age; the
prevalence of PCP among these infants was very
similar to that among adults with AIDS. These
observations suggest that P. carinii is common in
the environment, consistent with the suggestion
that the organism is easily acquired.
While the association with geographic
distribution is consistent with recent acquisition
of clinical infections, the actual source of the
infection is not known. The rat P. carinii model
suggests direct (animal-to-animal) transmission
(5,26,27); however, if person-to-person transmis-
sion does occur, it has not been shown to be of
epidemiologic significance (28,29). PCR amplifi-
cation of P. carinii DNA from spore traps from
various sites supports the possibility of an
environmental source (30-33), but no specific
plant, animal, or soil source has been identified.
Identification of a specific environmental reser-
voir for P. carinii f. sp. hominis, if one exists,
could elucidate disease transmission and im-
prove prevention efforts.
The rate of coinfection with multiple
P. carinii strains by multilocus typing was 17.8%
(34 of 191). Of the 191 patients for whom both
genes were typed, 20 (10.5%) were coinfected at
the mtlsurRNA locus and 19 (9.9%) at the DHPS
locus. Five patients tested positive for multiple
strains concurrently at both loci. While the
sensitivity to detect coinfections was similar for
both genes, concordance between the two genes
was very low in detecting coinfections with
multiple strains in any particular isolate—only
four genotypes can be detected at each individual
locus. When the loci are considered together,
however, the sensitivity is greatly increased,
because the number of possible genotypes
increases from 4 to 16, 14 of which were observed
in this study.
The 17.8% coinfection rate is within the 10%
to 30% range reported by other investigators
using DNA sequencing-based approaches
(14,22,34). Although coinfection rates as high as
69% have been reported with single-strand
conformation polymorphism analysis (35), these
differences can probably be resolved by two
considerations. The first is the sensitivity of the
selected locus, which is a function of the genetic
variability or evolutionary rate of the locus (i.e.,
the more variable the locus, the greater its
sensitivity to detect a different genotype). In this
study, mtlsurRNA and DHPS displayed a high
degree of genetic conservation, with only four
alleles detected at each locus, all of which have
been observed (11,16,17). Because these are
relatively slowly evolving genes, the sensitivity
to detect coinfections with multiple strains is
expected to be less than in a faster evolving locus.
The second consideration is PCP prophylaxis.
Correlation between primary PCP and coinfection
with multiple strains suggests that patients may
be exposed to multiple P. carinii strains over
extended periods and harbor short-lived, latent
infections. Consequently, patients who have not
been treated are more likely to have been exposed
(and to harbor) multiple P. carinii strains. On the
other hand, patients who have been treated for
PCP at least once and are taking secondary
prophylaxis are less likely to become reinfected.
This hypothesis is consistent with indications
that  P. carinii is ubiquitous in the environmentResear Resear Resear Resear Research ch ch ch ch
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and exposure in humans is commonplace (22,23).
A short latency period has been suggested (36)
and is consistent both with coinfections’
correlating with primary PCP and allelic
frequency distributions’ correlating with the
place of diagnosis but not the place of birth.
The question of latency and reactivation
versus recent acquisition is of great importance
as it relates to prevention. If the preponderance
of infections in humans results from activated
latent infections, chemoprophylaxis is the only
method of preventing disease. If, however,
infections are actively acquired, identifying
specific sources of infection would lead to other
methods of prevention and reduce dependence on
antimicrobial agents.
The most important clinical implication of
the polymorphism observed specifically at the
DHPS locus relates to the emergence of possible
antimicrobial resistance; however, the observa-
tion of different DHPS alleles in P. carinii
populations also has implications for transmis-
sion routes and patterns and the possibility of
person-to-person transmission.
In human P. carinii isolates, four distinct
genotypes have been reported at the DHPS locus
(16,17). All four of these DNA base changes result
in amino acid substitutions at an important
structural position, in an otherwise very highly
conserved gene (17,37). Genotype 1 in our study
corresponds to the “wild-type” genotype, as
defined by the only allele observed in P. carinii
from any other mammalian species (16,17).
Genotype 2 is a point mutation that results in a
threonine-to-alanine substitution at amino acid
position 55. Genotype 3 is also a point mutation,
resulting in a proline-to-serine substitution at
amino acid position 57. Genotype 4 is a double
mutant, which has alanine at position 55 and
serine at position 57. This particular mutation
has rarely been associated with failure of both
TMP-SMZ treatment (38) and prophylaxis (17).
The presence of polymorphism at two different
positions, both associated with amino acid
substitutions, at a gene locus that otherwise
lacks variability, is itself indicative of pro-
nounced selective pressure. Such a degree of
selection is not itself an indication of
resistance, but certainly suggests that resis-
tance may be emerging. Mutations in this same
region of the DHPS molecule have been
correlated with specific antimicrobial resis-
tance to sulfa drugs in a number of other
microorganisms, including Plasmodium falci-
parum (39), Streptococcus pneumoniae (40),
Streptococcus pyogenes (41), Escherichia coli (42),
and Neisseria meningitidis (43).
The two single mutations are uncommon by
themselves (5.9% for genotype 2 and 2.3% for
genotype 1), yet 50% of all isolates have the
double mutant, which suggests that, alone,
neither mutation is highly selected, but together
they pose a very strong selective advantage. If
humans are dead-end hosts for P. carinii, how
can such a pronounced degree of polymorphism
be explained? Person-to-person transmission
may be essential to allow genetic selection to
occur, resulting in this polymorphism.
Geographic variation in allelic frequency
detected at the mtlsurRNA locus is not
unexpected, even though other studies with
smaller sample sizes failed to observe differences
(11). Mitochondrial DNA sequence data have
been highly useful in detecting intraspecific
differences between populations of diverse
organisms (44,45). Perhaps more unexpected,
however, was the detection of geographic
variation at the DHPS locus. Unlike mtlsurRNA,
because it encodes a gene product that is the
target of the primary anti-P. carinii drug TMP-
SMZ, the DHPS locus is assumed to be subject to
intense selection pressure. Consequently, this
selection might be expected to override any
potential variation from geographic separation or
geographic patterns to reflect TMP-SMZ expo-
sure patterns. The relative frequency of the
double mutant genotype was much higher in
samples from the West Coast, particularly San
Francisco, than in samples from Atlanta
(Figure 2). The reason for this difference is not
obvious because in preliminary multivariate
analysis conducted with samples from Atlanta
and San Francisco, when the data are
controlled for sulfa exposure, place of diagnosis
is still the most significant factor influencing
the frequency of the double mutant genotype
(data not shown). Explanations for this
observation are being evaluated.
An overall frequency of approximately 50%
for the DHPS double mutant genotype is
somewhat higher than that reported in other
recent studies (46,47). The reason for this
observation is also unclear. One possible
explanation is that the samples were collected
more recently (March 1995 to June 1998) and
therefore reflect a sulfa-induced increase inResear Resear Resear Resear Research ch ch ch ch
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frequency of the double mutant. Most patients
were from San Francisco and Atlanta, the two
populations that showed the greatest difference
in genotype frequency at the DHPS locus. Sample
collection in Atlanta began in 1995, but in San
Francisco the earliest samples were from 1997.
When we stratified the patients in Atlanta by
date, 1995-96 versus 1998-99, we saw no
significant difference in the frequency of mutant
genotypes. Similarly, when we stratified data for
San Francisco by date, 1997 versus 1998-99, we
saw no differences. Consequently the frequency
of the mutation did not change during this study
period, nor does the variation observed according
to geography appear to be confounded by the
dates when specimens were collected.
Conclusions
 The pattern of allelic variation differed at
each of the cities where samples were obtained,
and this variation correlated with the place of
diagnosis but not with the place of birth.
Coinfection with multiple P. carinii genotypes
was associated with primary rather than
secondary PCP. The position 55/57 double
mutant accounted for 50% of all genotypes of the
DHPS locus examined. These observations
suggest the following possibilities, which contra-
dict much of the current opinion on the
epidemiology and transmission of PCP: Most
cases of PCP are not a result of infections
acquired very early in life; infections are actively
acquired from a relatively common source
(humans or the environment); and humans,
while not necessarily involved in direct infection
of other humans, are nevertheless important in
the transmission cycle of P. carinii f. sp. hominis.
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